ライフサイエンスコーパス: triamcinolone

1 Ten eyes received mitomycin C (MMC) and triamcinolone.

2 ontaminated, compounded combined bevacizumab-triamcinolone.

3 ns-scleral delivery of posterior sub-Tenon's triamcinolone.

4 ined high after treatment with intramuscular triamcinolone.

5 the most common complications of intraocular triamcinolone.

6 examethasone or intravitreal/subconjunctival triamcinolone.

7 ema responded to intravitreal treatment with triamcinolone.

8 6 weeks of successful treatment with topical triamcinolone.

9 ook both colchicine (0.6 mg/twice a day) and triamcinolone.

10 travitreal treatment were offered peribulbar triamcinolone.

11 id responsiveness testing with intramuscular triamcinolone.

12 per QALY compared with laser treatment plus triamcinolone.

13 ated successfully with a second injection of triamcinolone.

14 The patient was treated with intravitreal triamcinolone (0.1 mL/4 mg).

15 ory therapies such as hydrocortisone (2.5%), triamcinolone (0.1%), or tacrolimus ointment.

16 ory causes, such as hydrocortisone (2.5%) or triamcinolone (0.1%); topical neuropathic agents for neu

17 400 mg/kg) and an intramuscular injection of triamcinolone (0.8 mg/kg) 1 d before talc instillation a

18 hasone intravitreal implant (2 citations) or triamcinolone (1 citation), although cataract and glauco

19 corticosteroid therapy for treatment of DME: triamcinolone (1), dexamethasone (4), and fluocinolone a

20 ived an intravitreal DEX 0.7 mg (Ozurdex) or triamcinolone (2 mg) (Triesence) for postvitrectomy ME b

21 , intravitreal bevacizumab (5), intravitreal triamcinolone (2), intravitreal dexamethasone implant (1

22 t with clobetasol ointment and intralesional triamcinolone; 2 patients also underwent open superficia

23 on (2 patients), intravitreal or sub-Tenon's triamcinolone (3 patients), and observation (4 patients)

24 The most frequently cited agents were triamcinolone (33.3%), brolucizumab (13.3%), and bevaciz

25 jection + prompt laser; or (4) intravitreous triamcinolone (4 mg) + prompt laser.

26 ined intravitreal corticosteroids, including triamcinolone (4) and the dexamethasone implant (2).

27 e patients received a mixture of 1 mL of the triamcinolone, 40 mg/mL, and 1 mL of 0.5% bupivacaine hy

28 week run-in period of treatment with inhaled triamcinolone (400 microg twice per day).

29 ed-release dexamethasone-5-FU device and the triamcinolone-5-FU suspension effectively inhibit the pr

30 ells (HTM) treated with dexamethasone (DEX), triamcinolone acetate, and prednisolone acetate by TaqMa

31 bone loss and who were treated with inhaled triamcinolone acetonide (100 microg per puff).

32 viability of ARPE-19 cells after exposure to triamcinolone acetonide (200 microg/mL) alone without th

33 The R28 cells exposed to triamcinolone acetonide (200 microg/mL) without the vehi

34 intervention: Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevaci

35 Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevaci

36 week run-in period of treatment with inhaled triamcinolone acetonide (400 microg twice per day).

37 d with the chaperones in the presence of [3H]triamcinolone acetonide ([3H]TA), which binds to the rec

38 to -6), response to a characterizing dose of triamcinolone acetonide (B, -8.4 mL/1% change FEV(1) pos

39 l retinal thickness (CRT) after intravitreal triamcinolone acetonide (IVT) injection for macular edem

40 Intravitreal triamcinolone acetonide (IVTA) is an effective treatment

41 usion (SCORE) Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing

42 In 3 eyes, intravitreal triamcinolone acetonide (IVTA) was injected within 8 wee

43 surface of the plate, and 20 mg of subtenon triamcinolone acetonide (Kenalog, Bristol-Myers Squibb)

44 tocol, and swollen joints were injected with triamcinolone acetonide (maximum dosage 80 mg per month)

45 Intravitreal triamcinolone acetonide (PropBL ITA/PropBL PTA, hazard r

46 ceived an average of 1.6 posterior sub-Tenon triamcinolone acetonide (PSTA) injections in the 12 mont

47 ate the efficacy of injecting suprachoroidal triamcinolone acetonide (SCTA) plus intravitreal bevaciz

48 combined use of suprachoroidal injection of triamcinolone acetonide (SCTA) using a modified custom n

49 aoperative subconjunctival injection of 2 mg triamcinolone acetonide (TA) alone.

50 GR in complex with the potent glucocorticoid triamcinolone acetonide (TA) and a fragment of the small

51 culation on transscleral drug delivery using triamcinolone acetonide (TA) as a model drug.

52 racterize the safety and pharmacodynamics of triamcinolone acetonide (TA) delivered by this technique

53 ion of MR and GR activated by aldosterone or triamcinolone acetonide (TA) leads to significant transa

54 the posterior suprachoroidal placement of a triamcinolone acetonide (TA) suspension.

55 cy and safety of suprachoroidal injection of Triamcinolone Acetonide (TA) using a microinjector as a

56 At present, intralesional multi-injection of triamcinolone acetonide (TA) using a syringe is one of t

57 A novel conjugate of mitomycin C (MMC) and triamcinolone acetonide (TA) was synthesized using gluta

58 ating agents dexamethasone (Dex), IL-10, and triamcinolone acetonide (TA) were used to antagonize pro

59 Three agents-prednisolone acetate (PA), triamcinolone acetonide (TA), and lipid-based artificial

60 ty guidelines) and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors

61 dard topical corticosteroid (TCS) treatment, triamcinolone acetonide (TA), on the formation, maintena

62 treated with 100 microM CoCl(2), 1 microg/mL triamcinolone acetonide (TA), or both.

63 oid receptor (GR) and c-jun transcription in triamcinolone acetonide (TA)-treated AtT-20 cells.

64 The inherent electron-capture properties of triamcinolone acetonide (TAA) fatty acid conjugates were

65 Triamcinolone acetonide (TAA) is an anti-inflammatory st

66 Intra-articular administered triamcinolone acetonide (TAA) is one of the drug treatme

67 , M: 770 microg, H: 1,540 microg per day and triamcinolone acetonide (TAA) L: 400 microg, M: 800 micr

68 properties of the C21 acetate derivative of triamcinolone acetonide (TAA) under methane chemical ion

69 ed this method to quantify the low levels of triamcinolone acetonide (TACA) in porcine plasma followi

70 formulations encapsulating the model steroid triamcinolone acetonide (Tr-A) were implanted subcutaneo

71 rong cytochrome P-450 3A (CYP3A) inducer] or triamcinolone acetonide (weak CYP3A inducer) produced do

72 CT-guided TMJ injections of corticosteroid (triamcinolone acetonide [n = 16] or triamcinolone hexace

73 two trans-Tenon's retrobulbar injections of triamcinolone acetonide after explaining the procedure a

74 aser may be more effective than intravitreal triamcinolone acetonide alone.

75 uided intra-articular hip injection of 40 mg triamcinolone acetonide and 4 mL 1% lidocaine hydrochlor

76 ization was improved in 15 patients by using triamcinolone acetonide and in the remaining 15 patients

77 Intravitreal triamcinolone acetonide and the IDI were superior to PTA

78 ent with inhaled albuterol and intramuscular triamcinolone acetonide and yearly for 5 years.

79 (GCs) dexamethasone, mometasone furoate, and triamcinolone acetonide are pharmaceutical mainstays to

80 corticosteroids; intralesional injection of triamcinolone acetonide at the ulcer margin; topical cro

81 hydroxyl-terminated polyamidoamine dendrimer-triamcinolone acetonide conjugate (D-TA) is selectively

82 The effects of triamcinolone acetonide cream 0.025% were assessed based

83 sion of ACE2 and TMPRSS2, but treatment with triamcinolone acetonide did not decrease expression of e

84 This study compared computer-modeled triamcinolone acetonide diffusion after posterior sub-Te

85 Treatment with topical triamcinolone acetonide dramatically reduced pathology b

86 hma receiving beclomethasone dipropionate or triamcinolone acetonide during a 2-wk, single-blind, run

87 cts of intra-articular injection of 40 mg of triamcinolone acetonide every 3 months on progression of

88 Intravitreal triamcinolone acetonide followed by laser may be more ef

89 tained-release suspension releasing 5-FU and triamcinolone acetonide for 1 month.

90 50, 100, and 200 microg/mL concentration of triamcinolone acetonide for 2, 6, and 24 hours.

91 ty and efficacy of suprachoroidally injected triamcinolone acetonide formulation (CLS-TA), a suspensi

92 retical model predicts efficient delivery of triamcinolone acetonide from the posterior sub-Tenon's s

93 In the triamcinolone acetonide group, 12 months after surgery t

94 and sustainably released the corticosteroid triamcinolone acetonide in a rat model of patellar tendo

95 us); Protocol I (Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photoc

96 th intravitreal injections of bevacizumab or triamcinolone acetonide in patients with macular edema a

97 hanges following suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA),

98 ity after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprac

99 oroidal CLS-TA (proprietary formulation of a triamcinolone acetonide injectable suspension), and 64 r

100 e comparative study showed that intravitreal triamcinolone acetonide injection and the dexamethasone

101 l ranibizumab injection compared to subtenon triamcinolone acetonide injection at cataract operation.

102 effectiveness superior to that of periocular triamcinolone acetonide injection for these outcomes.

103 ion group, phacoemulsification with subtenon Triamcinolone acetonide injection group and phacoemulsif

104 Intraoperative intravitreal triamcinolone acetonide injection induces earlier and ma

105 endolaser photocoagulation and intravitreal triamcinolone acetonide injection resulted in a complete

106 Intravitreal triamcinolone acetonide injection therapy, in particular

107 , 3 days, and 1, 2, 3, 4, and 8 weeks) after triamcinolone acetonide injection, with 6 controls witho

108 periocular, suprachoroidal, and intravitreal triamcinolone acetonide injections and intravitreal dexa

109 received bevacizumab injections, 35 (44.9%) triamcinolone acetonide injections, and 5 (6.4%) a dexam

110 Triamcinolone acetonide is toxic to proliferating cells

111 ss the efficacy of intravitreal injection of triamcinolone acetonide IVTA combined with standard phac

112 n after posterior sub-Tenon's injection with triamcinolone acetonide levels in experimental undiluted

113 The theoretical model predicted that triamcinolone acetonide levels in systemic blood, vitreo

114 Intravitreal triamcinolone acetonide may be more effective than laser

115 itreal injections of ranibizumab or subtenon triamcinolone acetonide may prevent further progression

116 rectomy and ILM peeling assisted with either triamcinolone acetonide or infracyanine green staining i

117 However, triamcinolone acetonide staining is associated with an i

118 Random assignment into 2 groups: 40-mg triamcinolone acetonide subacromial CSI versus 6 session

119 and durability advantages of investigational triamcinolone acetonide suspension (CLS-TA; Clearside Bi

120 Sedimentation of 1.0 mL triamcinolone acetonide suspension for intravitreal use

121 bits received a subconjunctival injection of triamcinolone acetonide to one eye.

122 ith 14 days pre-treatment with INCS (220 mug triamcinolone acetonide twice daily).

123 In summary, the use of inhaled triamcinolone acetonide was associated with loss of BMD

124 Carbon-11-labeled triamcinolone acetonide was formulated as the commercial

125 vehicle and with the vehicle alone, in which triamcinolone acetonide was suspended.

126 ning to glaucoma in response to intravitreal triamcinolone acetonide will be reviewed.

127 the prospective Suprachoroidal Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in

128 (>/=24 weeks) laser, or 4 mg of intravitreal triamcinolone acetonide with prompt laser.

129 duction when the R28 cells were treated with triamcinolone acetonide with vehicle (200 microg/mL) for

130 y of ARPE-19 and R28 cells after exposure to triamcinolone acetonide with vehicle 200 microg/mL for 2

131 Triamcinolone acetonide with vehicle caused a greater re

132 ial dehydrogenase activity when treated with triamcinolone acetonide without the vehicle at any of th

133 collected at baseline, after intramuscular (triamcinolone acetonide) corticosteroid treatment, and a

134 ons (9453 ranibizumab, 5386 bevacizumab, 935 triamcinolone acetonide, 121 pegaptanib sodium) were rev

135 dophthalmitis per injection was 2 in 935 for triamcinolone acetonide, 3 in 9453 for ranibizumab, and

136 andomly allocated to receive an injection of triamcinolone acetonide, 40 mg, either IM in the ipsilat

137 They used inhaled triamcinolone acetonide, 600 mcg, or placebo, twice dail

138 Topical therapy with moderate doses of triamcinolone acetonide, an anti-inflammatory glucocorti

139 corticosteroids (budesonide, dexamethasone, triamcinolone acetonide, and dexamethasone acetate) rang

140 e Flt23k nanoparticles, blank nanoparticles, triamcinolone acetonide, and PBS groups following subcon

141 ant Q642V, which has an altered affinity for triamcinolone acetonide, dexamethasone, and corticostero

142 Four synthetic glucocorticoids (triamcinolone acetonide, fluocinolone acetonide, clobeta

143 tonide formulation (CLS-TA), a suspension of triamcinolone acetonide, in improving vision among patie

144 e suggested beneficial treatment effects for triamcinolone acetonide, interferon alpha-2a, and supple

145 ne the human biodistribution and kinetics of triamcinolone acetonide, labeled with 11C, formulated an

146 ular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of these thera

147 Intravitreal triamcinolone acetonide, pars plana vitrectomy, oral pro

148 Triamcinolone acetonide, the most commonly used intravit

149 in the ARPE-19 cells when treated with both triamcinolone acetonide, with or without the vehicle at

150 he patient underwent periocular injection of triamcinolone acetonide, with resolution of the subretin

151 PVD) confirmed by intraoperative findings of triamcinolone acetonide-assisted pars plana vitrectomy (

152 In contrast, triamcinolone acetonide-induced luciferase activity was

153 uced cataract was observed in 4 intravitreal triamcinolone acetonide-treated patients (12%).

154 sion was documented in 22 (69%) intravitreal triamcinolone acetonide-treated vs 11 (34%) intravitreal

155 ile, and a slightly long-lasting effect than triamcinolone acetonide.

156 a potentiating effect on the cytotoxicity of triamcinolone acetonide.

157 on of xylocaine alone or in combination with triamcinolone acetonide.

158 ns were assessed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (

159 nd frequent intramuscular administrations of triamcinolone achieved control of both the oral and geni

160 gram with paired (before and 2-3 weeks after triamcinolone administration) sputum data.

161 d with clobetasol ointment and intralesional triamcinolone, alone or in combination with open superfi

162 Intravitreal triamcinolone also appears to be associated with a reduc

163 sis factor biologic agents, and intravitreal triamcinolone and antivascular endothelial growth factor

164 undergoing cataract surgery, peri-operative triamcinolone and bevacizumab may blunt the progression

165 Adjunctive use of both triamcinolone and bevacizumab with PRP lead to a greater

166 Serum triamcinolone and cortisol levels were inversely correla

167 t, and pegaptanib) and intraocular steroids (triamcinolone and dexamethasone).

168 Intravitreal bevacizumab, intravitreal triamcinolone and laser photocoagulation appear to trans

169 6 to BCT plus ultrasound guided injection of triamcinolone and lidocaine, and 66 to BCT plus ultrasou

170 id responsiveness testing with intramuscular triamcinolone and participants receiving biologics.

171 ecently, intraocular corticosteroids such as triamcinolone and steroid-loaded vitreal inserts and imp

172 d- or third-trimester exposure to intranasal triamcinolone and the risk of SGA (OR, 1.06; 95% CI, 0.7

173 end of the run-in, all subjects discontinued triamcinolone and were randomized to continued colchicin

174 Three steroids (betamethasone, triamcinolone, and methylprednisolone) and three local a

175 rative intravitreal bevacizumab, sub-Tenon's triamcinolone, and panretinal photocoagulation (PRP) aft

176 ate steroids cortivazol, methylprednisolone, triamcinolone, and prednisolone.

177 NPV (99.7%-100%) were codes for aflibercept, triamcinolone, and the dexamethasone implant.

178 number of medications, the most common being triamcinolone, antivascular endothelial growth factor (V

179 vs. trial in the in placebo, salmeterol, and triamcinolone arms, respectively.

180 who had undergone a course of intramuscular triamcinolone at baseline and at 2 annual follow-up visi

181 d 45 were treated with intravitreal therapy (triamcinolone, bevacizumab, and/or dexamethasone).

182 ts With prednisolone, methylprednisolone, or triamcinolone, blood flow was rapidly and completely sto

183 are discussed, as is the use of intravitreal triamcinolone both at the time of cataract surgery and p

184 intranasal corticosteroids (eg, fluticasone, triamcinolone, budesonide, mometasone) and should be sel

185 intranasal corticosteroid (eg, fluticasone, triamcinolone, budesonide, mometasone) either alone or i

186 nt in lung function and asthma control after triamcinolone, but these differences were limited to phe

187 l injections, and the fact that intravitreal triamcinolone can cause cataract or glaucoma, use of the

188 stent asthma well controlled by low doses of triamcinolone cannot be switched to salmeterol monothera

189 roids (prednisolone, methylprednisolone, and triamcinolone) caused often immediate and complete cessa

190 cortisol suppression: flunisolide-CFC - 936; triamcinolone-CFC - 787; beclomethasone-CFC - 548; fluti

191 red dose inhaler [MDI], flunisolide-CFC, and triamcinolone-CFC), only the placebo group and fluticaso

192 e osteoarthritis, 2 years of intra-articular triamcinolone, compared with intra-articular saline, res

193 Triamcinolone counteracted the coregulation of these gen

194 daily [QD], 0.5% QD, 0.15% QD), vehicle, or triamcinolone cream (0.1% BID for 4 weeks, then vehicle

195 Treatment of patients with triamcinolone decreases SDF-1 levels in the vitreous, wi

196 The triamcinolone deposit was visible on infrared imaging an

197 The immunosuppressive effect of triamcinolone does not appear to increase the risk of en

198 salmeterol, a substantial reduction (50%) in triamcinolone dose can occur without a significant loss

199 Maternal exposure to intranasal triamcinolone during pregnancy was not associated with t

200 ss well for patients treated with salmeterol/triamcinolone during the entire study duration, with mid

201 tively, for patients treated with salmeterol/triamcinolone during the first half of the SLIC study an

202 for potential confounders, use of intranasal triamcinolone during the first trimester of pregnancy wa

203 % CI) of treatment failure at the end of the triamcinolone elimination phase in the salmeterol-minus

204 Triamcinolone enhanced iOCT imaging revealed strong vitr

205 omes consisted of risks of fracture based on triamcinolone equivalents received in subgroups of patie

206 rimary outcome was risk of fracture by total triamcinolone equivalents received.

207 , Quebec, Canada, from 1998-2008, intranasal triamcinolone-exposed, other intranasal corticosteroid-e

208 rom a series of 17 treated with intravitreal triamcinolone for retinal vascular disease and diabetes

209 mly assigned to continue both salmeterol and triamcinolone for the remaining 16 weeks (active control

210 y, tolerability and efficacy of SC delivered triamcinolone further supports potential of SC small mol

211 l group had more treatment failures than the triamcinolone group (13/54 [24%] vs 3/54 [6%]; P =.004),

212 elated adverse events compared with 5 in the triamcinolone group and had a small increase in hemoglob

213 reatment was not significantly longer in the triamcinolone group than in the salmeterol group.

214 In the triamcinolone group visual acuity showed improved outcom

215 icant differences between the salmeterol and triamcinolone groups were observed for conventional outc

216 r inhibition of IL-4 protein was as follows: triamcinolone > dexamethasone > betamethasone > hydrocor

217 bevacizumab (Avastin) and preservative-free triamcinolone, has significantly expanded our treatment

218 steroid (triamcinolone acetonide [n = 16] or triamcinolone hexacetonide [n = 7]).

219 injection of compounded combined bevacizumab-triamcinolone in a period of 3 weeks had subtle, nonspec

220 s (intravitreal dexamethasone and peribulbar triamcinolone) in treating pseudophakic macular edema (P

221 The triamcinolone-induced difference in the post-bronchodila

222 For each 5% decrement in the triamcinolone-induced difference the FEV1% predicted, th

223 tion was observed and treated with sub-tenon triamcinolone injection followed by intravitreal injecti

224 mcinolone is better than after orbital floor triamcinolone injection, but that a single intraoperativ

225 limiting membrane peeling, and intravitreal triamcinolone injection.

226 my, posterior capsulectomy, and intravitreal triamcinolone injection.

227 reported case of treatment with retrobulbar triamcinolone injections.

228 mproved temporarily with sub-Tenon's capsule triamcinolone injections.

229 eported management approach with retrobulbar triamcinolone injections.

230 ound guided intra-articular hip injection of triamcinolone is a treatment option to add to BCT for pe

231 Triamcinolone is an affordable (which is of particular i

232 le intraoperative orbital floor injection of triamcinolone is as effective as a 4-week course of post

233 t in CME and inflammation after intravitreal triamcinolone is better than after orbital floor triamci

234 To compare the efficacy of intravitreal triamcinolone (IVT) and intravitreal bevacizumab (IVB),

235 east as much visual benefit for intravitreal triamcinolone (IVTA) versus laser; (2) a subgroup analys

236 umab (L+B), or focal laser plus intravitreal triamcinolone (L+T) injections.

237 improvements than eyes managed with laser or triamcinolone + laser followed by very deferred ranibizu

238 ser/very deferred ranibizumab (N = 198), and triamcinolone + laser/very deferred ranibizumab (N = 125

239 aser and laser/very deferred ranibizumab and triamcinolone + laser/very deferred ranibizumab was 4.4

240 eau in the range 15 to 25 ng/mL, while serum triamcinolone levels peaked at day 3 near 35 ng/mL and p

241 raction effect favouring BCT plus ultrasound-triamcinolone-lidocaine (-1.70 (-3.10 to -0.30)).

242 ths was reported between BCT plus ultrasound-triamcinolone-lidocaine compared with BCT plus ultrasoun

243 months was reported with BCT plus ultrasound-triamcinolone-lidocaine compared with BCT: mean differen

244 One participant in the BCT plus ultrasound-triamcinolone-lidocaine group with a bioprosthetic aorti

245 lly reduced costs, and all treatments except triamcinolone monotherapy increased QALYs.

246 Laser monotherapy and triamcinolone monotherapy were less effective and more c

247 ne plus ibuprofen (n = 10), doxycycline plus triamcinolone (n = 10), or placebo (n = 10).

248 nibizumab (n = 11), bevacizumab (n = 20), or triamcinolone (n = 19).

249 Intra-articular triamcinolone (n = 70) or saline (n = 70) every 12 weeks

250 ies of eyes after intravitreal injections of triamcinolone obtained from a single compounding pharmac

251 yes) who received intravitreal injections of triamcinolone obtained from a single compounding pharmac

252 Intravitreal injections of triamcinolone obtained from a single lot were subsequent

253 ed in 82% (14/17) of eyes after intravitreal triamcinolone obtained from the same lot.

254 he combination group compared with 0% in the triamcinolone only group.

255 combination group compared with 47.6% in the triamcinolone-only group and 42.4% in the triamcinolone

256 Laser treatment, intraocular injections of triamcinolone or a vascular endothelial growth factor (V

257 with 130 selective lumbar nerve blocks with triamcinolone or betamethasone.

258 ogists performing intravitreal injections of triamcinolone or other medications of the risk for endop

259 aries per millimeter for methylprednisolone, triamcinolone, or prednisolone, respectively, vs 21.0, 2

260 ofen (P = .03), and 1 given doxycycline plus triamcinolone (P = .14).

261 Experimental vitreous levels of triamcinolone peaked at 111 ng/mL at day 1, then reached

262 he triamcinolone-only group and 42.4% in the triamcinolone plus blank nanoparticle group.

263 ranibizumab plus deferred laser (R+dL), and triamcinolone plus laser (T+L), effectiveness through 10

264 bizumab plus prompt or deferred laser versus triamcinolone plus prompt laser.

265 On day 14, 42% of triamcinolone recipients and 53% of betamethasone recipi

266 t in low back pain (P = .26), whereas 49% of triamcinolone recipients and 55% of betamethasone recipi

267 t in low back pain (P = .38), whereas 52% of triamcinolone recipients and 57% of betamethasone recipi

268 (P = .04, Fisher exact test), whereas 55% of triamcinolone recipients and 57% of betamethasone recipi

269 On day 7, 45% of triamcinolone recipients and 58% of betamethasone recipi

270 On day 3, 42% of triamcinolone recipients and 58% of betamethasone recipi

271 ive nerve root blocks with betamethasone and triamcinolone reduced low back pain and lower extremity

272 Intra-articular triamcinolone resulted in significantly greater cartilag

273 The bevacizumab and triamcinolone results are promising, but the inclusion c

274 dophakic patients, first-line treatment with triamcinolone seems to be the most cost-effective option

275 Triamcinolone staining of the vitreous improves visualiz

276 rations of: dexamethasone (DEX) (0.3 mg/mL), triamcinolone (TA; 0.4-4 mg/mL), or PBS.

277 tal findings demonstrate low levels of serum triamcinolone that alter systemic cortisol levels and hi

278 nanoparticles pre-bound with electro-active triamcinolone, the cortisol level is detected based on i

279 nto: 1) following injections of bevacizumab, triamcinolone, their combination, or ranibizumab regardl

280 Patients were randomly assigned to continue triamcinolone therapy (400 microg twice per day; n = 54)

281 persistent asthma suboptimally controlled by triamcinolone therapy alone but whose asthma symptoms im

282 Patients continued triamcinolone therapy and were randomly assigned to rece

283 However, total elimination of triamcinolone therapy results in a significant deteriora

284 of the salmeterol-minus group 8 weeks after triamcinolone therapy was eliminated compared with 13.7%

285 nd dose-dependent manner, the binding of [3H]triamcinolone to immunoprecipitated GR from mouse L929 f

286 horylation of c-Fos and ERK1/2 were found in triamcinolone-treated mutant retinas.

287 of the salmeterol-minus group 8 weeks after triamcinolone treatment was reduced compared with 2.8% (

288 % (for 8 weeks) then eliminate (for 8 weeks) triamcinolone treatment.

289 We aim to estimate the safety of intranasal triamcinolone use during pregnancy, which was introduced

290 tamer by following signal from the displaced triamcinolone using square wave voltammetry at patterned

291 olled, double-blind trial of intra-articular triamcinolone vs saline for symptomatic knee osteoarthri

292 Pregnancy exposure to intranasal triamcinolone was not significantly associated with the

293 crocatheterization for posterior delivery of triamcinolone was possible in all attempts using the ill

294 rid treatment and intravitreal injections of triamcinolone, was selected to receive a cycle of three

295 n additional 6 letters correct compared with triamcinolone with laser at an additional cost of $19 21

296 pseudophakics, the ICER value for comparison triamcinolone with laser versus ranibizumab with deferre

297 with deferred laser (P = .001), and 37% with triamcinolone with prompt laser (P = .10).

298 itochondrial dehydrogenase activity than did triamcinolone without vehicle, in both cell lines, altho